Rubitecan (INN, trade name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, a member of the Otsuka Group).
Rubitecan (INN, trade name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, a member of the Otsuka Group).
==History== On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA, and was accepted for filing in March 2004.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).